NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product.

Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020.

London, May 20th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced a collaboration with University Hospital Aachen to initiate a cancer therapy programme to bring a novel radiopharmaceutical product to patients with HER2 positive breast cancer.

The programme will utilise Nanomab’s next generation NM-02 radiopharmaceutical product (a theranostic pairing of a diagnostic and a therapeutic medical radioisotope coupled to a camelid single domain antibody) targeting a First in Human (FIH) administration in Q4 2020.

 Paul Edwards, Nanomab’s CEO commented, “We are delighted to announce this collaboration with the Department of Nuclear Medicine at University Hospital Aachen, which will allow us to assess the therapeutic benefits of Nanomab’s NM-02 product, following evaluations in preclinical models, on patients with advanced breast and other HER2 positive cancers such as gastric cancer. The aim is to  show that our product has the ability to shrink metastatic cancers and improve the quality of life for patients.”

 

 

For more information:

Paul Edwards. Tel: +44 (0)7771 575374

Email:  p.m.edwards@nano-mab.com

Media

Richard Hayhurst/Janet Joy RHApr

Tel: +44 (0)7711 821 527

richard@rhapr.eu or jan@rhapr.eu

 

Notes to editors

 

NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of radiopharmaceuticals. Our goal is to develop a pipeline of theranostics with our proprietary camelid antibody platform to address the unmet medical need for cancer patients across the world. www.nano-mab.com

Department of Nuclear Medicine at University Hospital RWTH Aachen (Head: Prof. Dr. Felix M. Mottaghy) provides advanced diagnostics and therapeutics with the help of radioisotopes. The department uses PET, PET-CT, and SPECT to ensure the patient is diagnosed accurately and rapidly and has experience in translational concepts with the ultimate goal to bring new approaches from bench to bedside. The preclinical facility is equipped with all necessary tools. Novel theranostic concepts have been established in recent years.  

 

To read more Press Release articles, click here.